MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/s1081-1206(10)61408-1

Медицинская библиотека · Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2004

Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis.

Bowen Tom, Greenbaum Joseph, Charbonneau Yves, Hebert Jacques, Filderman Ronald, Sussman Gordon, Del Carpio Jaime, Gold Milton, Keith Paul, Moote William, Cecchetto Steve, Cecchetto Ollie, Sharp Daniel, Broutin Olivier, André Claude

Клиническое исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Sublingual swallow immunotherapy has been increasingly recognized as a safe and efficacious alternative to parenteral specific immunotherapy.

OBJECTIVE

To determine the safety and efficacy of sublingual swallow immunotherapy ragweed allergen extract for rhinoconjunctivitis treatment starting just before and continuing through the ragweed pollen season.

METHODS

This randomized, double-blind, placebo-controlled study was performed in children and adults with a documented history of allergic rhinoconjunctivitis during ragweed season at 9 Canadian allergy centers. Active treatment was standardized extract of ragweed allergen administered as sublingual swallow drops at increasing doses starting shortly before the pollen season and maintenance doses continued daily during the season. Primary efficacy variables were symptom and medication scores, and secondary variables included global evaluation of efficacy and immunologic measurements.

RESULTS

Eighty-three patients were included in the safety analysis; 76 patients were included in the intent-to-treat analysis. Nine placebo recipients and 1 treatment recipient withdrew for lack of efficacy (P = .004). Nine patients in the treatment group withdrew because of adverse events, none serious (P = .003). Investigator evaluation of efficacy showed that significantly more patients improved and fewer deteriorated in the treatment group vs the placebo group (P = .047). Ragweed IgE and IgG4 levels increased significantly in treatment recipients vs placebo users (P < .001). Sneezing and nasal pruritus approached significant improvement in the treatment group vs the placebo group (P = .09 and .06, respectively). Quebec City experienced low pollen counts. Excluding Quebec City, significant improvement was seen for these 2 symptoms (P = .04).

CONCLUSION

Sublingual swallow immunotherapy seems to be safe and efficacious for ragweed rhinoconjunctivitis even when started immediately before the ragweed pollen season.

Для цитирования: Bowen Tom, Greenbaum Joseph, Charbonneau Yves, Hebert Jacques, Filderman Ronald, Sussman Gordon, Del Carpio Jaime, Gold Milton, Keith Paul, Moote William, Cecchetto Steve, Cecchetto Ollie, Sharp Daniel, Broutin Olivier, André Claude. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis.. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2004. DOI: 10.1016/s1081-1206(10)61408-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.